Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma By Ogkologos - September 21, 2026 123 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final 5-year analysis of overall survival in the IMCgp100-202 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR 2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical... May 26, 2022 Hopes for the future of cancer research – a video from... April 16, 2023 The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment... September 19, 2020 11 Children Orphaned and Unable to Pay for Funeral After Their... April 25, 2019 Load more HOT NEWS Sleep Issue Called Hypersomnolence Can Increase The Risk Of Diabetes And... ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to... A Short-Course of Induction Chemotherapy Followed by Chemoradiotherapy Significantly Improves Survival... Should People Over Age 75 Be Screened for Colorectal Cancer?
